254 related articles for article (PubMed ID: 16026265)
1. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
Thomas MC; Baynes JW; Thorpe SR; Cooper ME
Curr Drug Targets; 2005 Jun; 6(4):453-74. PubMed ID: 16026265
[TBL] [Abstract][Full Text] [Related]
2. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Williams ME
Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
[TBL] [Abstract][Full Text] [Related]
3. [Antioxidant and anti-AGE therapeutics: evaluation and perspectives].
Bonnefont-Rousselot D
J Soc Biol; 2001; 195(4):391-8. PubMed ID: 11938556
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions.
Bierhaus A; Ziegler R; Nawroth PP
Horm Res; 1998; 50 Suppl 1():1-5. PubMed ID: 9676989
[TBL] [Abstract][Full Text] [Related]
5. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
6. Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Engelen L; Stehouwer CD; Schalkwijk CG
Diabetes Obes Metab; 2013 Aug; 15(8):677-89. PubMed ID: 23279611
[TBL] [Abstract][Full Text] [Related]
7. Role of AGEs in diabetic nephropathy.
Fukami K; Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
[TBL] [Abstract][Full Text] [Related]
8. The role of AGEs in cardiovascular disease.
Jandeleit-Dahm K; Cooper ME
Curr Pharm Des; 2008; 14(10):979-86. PubMed ID: 18473849
[TBL] [Abstract][Full Text] [Related]
9. Blockade of diabetic vascular injury by controlling of AGE-RAGE system.
Myint KM; Yamamoto Y; Sakurai S; Harashima A; Watanabe T; Li H; Takeuchi A; Yoshimura K; Yonekura H; Yamamoto H
Curr Drug Targets; 2005 Jun; 6(4):447-52. PubMed ID: 16026264
[TBL] [Abstract][Full Text] [Related]
10. Chelating activity of advanced glycation end-product inhibitors.
Price DL; Rhett PM; Thorpe SR; Baynes JW
J Biol Chem; 2001 Dec; 276(52):48967-72. PubMed ID: 11677237
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products.
Thomas MC
Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Jandeleit-Dahm KA; Lassila M; Allen TJ
Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
[TBL] [Abstract][Full Text] [Related]
13. Regulation of RAGE for attenuating progression of diabetic vascular complications.
Win MT; Yamamoto Y; Munesue S; Saito H; Han D; Motoyoshi S; Kamal T; Ohara T; Watanabe T; Yamamoto H
Exp Diabetes Res; 2012; 2012():894605. PubMed ID: 22110482
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
Takeuchi M; Takino J; Yamagishi S
Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
[TBL] [Abstract][Full Text] [Related]
15. [The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications].
Barbosa JH; Oliveira SL; Seara LT
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):940-50. PubMed ID: 18820805
[TBL] [Abstract][Full Text] [Related]
16. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
17. New potential agents in treating diabetic kidney disease: the fourth act.
Williams ME
Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
[TBL] [Abstract][Full Text] [Related]
18. Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
Goh SY; Cooper ME
J Clin Endocrinol Metab; 2008 Apr; 93(4):1143-52. PubMed ID: 18182449
[TBL] [Abstract][Full Text] [Related]
19. [Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Yamagishi S; Imaizumi T
Nihon Rinsho; 2005 Jun; 63 Suppl 6():136-8. PubMed ID: 15999696
[No Abstract] [Full Text] [Related]
20. Advanced glycation end products and diabetic nephropathy.
Thomas MC; Forbes JM; Cooper ME
Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
